Army 18.1 sbir phase i r & d contract for proposal A181-062-0830 titled "logistical and functional evaluation of synthoplatetm (intravenous synthetic platelet) technology for pre-hospital hemorrhage…
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH18C0370
- Awardee
-
Haima Therapeutics LLC UEI JKZPL4NA9V21
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $99,967
Award facts
- Opportunity
-
- HQ003418R1AAT Solicitation number
- Contract value 67% obligated
-
- $99,967.18 Current, with exercised options
- $148,203.61 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AN91 R&D- Medical: Other (Basic Research)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 126 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Cleveland, OH 44106, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
About this award
The Department of the Army Medical Command awarded a $148,203.61 Small Business Innovation Research (SBIR) Phase I contract to Haima Therapeutics LLC, a woman-owned small business, for research and development of a nanotechnology-enabled biosynthetic whole-blood surrogate for hemostatic resuscitation. This contract supports the Congressionally Directed Medical Research Programs' Combat Readiness-Medical Research Program under a Rapid Development and Translational Research Award. Additionally, Haima Therapeutics is engaged in the translational development of a lyophilized version of its synthetic platelet technology for hemorrhage control in remote damage control resuscitation applications through a subcontract from Case Western Reserve University. Haima Therapeutics has also received other federal grants from agencies such as the Defense Health Agency, National Science Foundation, and National Institutes of Health to support the core development and manufacturing scale-up of its synthetic platelet technology.
Description
Army 18.1 sbir phase i r & d contract for proposal A181-062-0830 titled "logistical and functional evaluation of synthoplatetm (intravenous synthetic platelet) technology for pre-hospital hemorrhage control"
Quick answers
Who was awarded contract W81XWH18C0370?
W81XWH18C0370 was awarded to Haima Therapeutics LLC by Medical Command (Department of the Army) on September 4, 2018.
How much is contract W81XWH18C0370 worth?
The government has obligated $99,967 on W81XWH18C0370. Its potential value, with all options, is $148,204.
Was contract W81XWH18C0370 competed?
The extent of competition for W81XWH18C0370 was full and open competition after exclusion of sources. The government received 126 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award